PHARMACEUTICAL CO-CRYSTALS

In the Pharmaceutical and
Fine Chemicals industries
the choice of the right solid
form can have a dramatic
influence on the successful
development of an active
pharmaceutical
ingredient
(API).
Until a few years ago, salts
and polymorphic solid forms
have been the classical
targets. Recently, however,
co-crystals have emerged as
a new alternative that has
stirred the interest in APIs
development
and
manufacturing areas, due to
the unique applications and
interesting advantages when
compared to other solid
forms.
Briefly, in co-crystals, the
API crystallizes with one or
more
neutral
“coformer”
components,
being
the
interactions
between
the
counterparts
weak,
non
covalent,
non
ionic
intermolecular forces.
Cocrystallisation
chemistry
can be used to improve the
physico-chemical properties
of APIs (solubility, stability,
hygroscopicity, flowability…)
and, in the manufacturing
processes, it can represent a
valuable tool to solve issues
related
to
purification,
resolution and stabilization of
products.
Any
new
co-crystal
(or
process involving co-crystals
in the API manufacturing
process) may be patented.
Last but not the least, a
recent FDA Guideline, related
to
co-crystals
Regulatory
classifications, is opening
interesting perspectives and
opportunities for the generic
industry in USA and Europe.
PHARMACEUTICAL CO-CRYSTALS
A not to miss opportunity for the
API generics industry
29 MAGGIO 2014
9.30
Registrazione partecipanti
10:00 Welcome and introductions
10:15 Value creation through new solid forms
development.
What is a co-crystal?
10:45 FDA Regulatory Classification of
Pharmaceutical co-crystals, April-2013.
Opportunities and limitations for the generic
industry in USA and Europe.
11.45 Coffee break
12:00 Co-crystallization technology.
Beyond pharmaceutical cocrystals
13.00 Lunch
14:15 Real case stories & Open discussion
Question & Answer
16.00 Concluding remarks
Speakers from Enantia (Italian language):
Joan Feixas - Llorenç Rafecas – Enrico Grassi
Enantia is a privately held company devoted to chemical research
and development, custom synthesis and crystal engineering, with
a strong focus on asymmetric chemistry and co-crystallization
technologies
Sede workshop:
CPA c/o Istituto Piero Pirelli
Viale Fulvio testi, 223 – 20162 Milano
29 MAGGIO 2014
PHARMACEUTICAL CO-CRYSTALS
A not to miss opportunity for the API generics industry
SCHEDA iscrizione
La presente scheda dovrà essere compilata ed inviata :
via email : [email protected]
O
via fax : 02 6692373
Azienda_____________________________________________________________________
Via_________________________________________________________________________
CAP___________Città ________________________________________Prov. ____________
Cognome___________________________________Nome____________________________
Funzione Aziendale____________________________________________________________
Tel ______________________________ email_____________________________________
Partita IVA aziendale___________________________________________________________
Quota di partecipazione:
-
€ 350,00 + IVA per il 1° partecipante non associato CPA
-
€ 270,00 + IVA per il 2° partecipante della stessa società non associata CPA
- € 250,00 + IVA per il 1° partecipante Associato CPA / Partner Enantia
- € 200,00 + IVA per il 2° partecipante stessa società Associato CPA / Partner Enantia
- € 320,00 + IVA per il 1° partecipante cliente 2014 eventi CPA
- € 240,00 + IVA per il 2° partecipante stessa società cliente 2014 eventi CPA
La quota comprende - documentazione ed attestato di partecipazione;
-
coffee break e colazione di lavoro.
Sede workshop : CPA c/o Istituto Pirelli
(Viale Fulvio Testi, 223 —Milano)
 Il pagamento dovrà essere effettuato tramite BONIFICO BANCARIO su
c/c presso della Banca Popolare di Sondrio - Agenzia 20 Milano intestato a
CPA (Viale Fulvio Testi, 223 – 20162 Milano - Partita IVA — Cod Fisc 04357310962)
IBAN :
IT 81 Z056 9601 6190 0000 2697X87
 Fattura quietanziata verrà emessa a riscontro dell’avvenuto pagamento
Per ogni informazione: Tel. 02 67380474 - [email protected]

Download Report